Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $81,872 - $109,088
-1,600 Reduced 12.21%
11,500 $621,000
Q1 2024

May 15, 2024

SELL
$60.67 - $89.12 $4.44 Million - $6.52 Million
-73,200 Reduced 84.82%
13,100 $892,000
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $2.95 Million - $5.51 Million
76,300 Added 763.0%
86,300 $5.4 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $869,400 - $1.36 Million
-20,000 Reduced 66.67%
10,000 $561,000
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $2.87 Million - $3.93 Million
-70,000 Reduced 70.0%
30,000 $1.36 Million
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $1.57 Million - $2.63 Million
40,000 Added 66.67%
100,000 $4.07 Million
Q3 2022

Nov 14, 2022

SELL
$61.1 - $83.78 $1.83 Million - $2.51 Million
-30,000 Reduced 33.33%
60,000 $3.92 Million
Q2 2022

Aug 15, 2022

SELL
$43.23 - $73.83 $1.73 Million - $2.95 Million
-40,000 Reduced 30.77%
90,000 $5.47 Million
Q1 2022

May 16, 2022

BUY
$53.19 - $79.24 $3.19 Million - $4.75 Million
60,000 Added 85.71%
130,000 $8.16 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $3.93 Million - $6.23 Million
56,000 Added 400.0%
70,000 $5.31 Million
Q3 2021

Nov 15, 2021

SELL
$110.2 - $156.64 $5.51 Million - $7.83 Million
-50,000 Reduced 78.13%
14,000 $1.57 Million
Q2 2021

Aug 16, 2021

SELL
$100.84 - $161.89 $6.2 Million - $9.96 Million
-61,500 Reduced 49.0%
64,000 $10.4 Million
Q1 2021

May 17, 2021

BUY
$110.72 - $210.04 $11.7 Million - $22.2 Million
105,500 Added 527.5%
125,500 $15.3 Million
Q2 2020

Aug 14, 2020

SELL
$38.5 - $76.05 $385,000 - $760,500
-10,000 Reduced 33.33%
20,000 $1.47 Million
Q4 2018

Feb 14, 2019

BUY
$22.73 - $42.34 $681,900 - $1.27 Million
30,000 New
30,000 $857,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.87B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.